193 related articles for article (PubMed ID: 20680707)
21. Salt formation to improve drug solubility.
Serajuddin AT
Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
[TBL] [Abstract][Full Text] [Related]
22. Amorphous Salts Solid Dispersions of Celecoxib: Enhanced Biopharmaceutical Performance and Physical Stability.
Mukesh S; Joshi P; Bansal AK; Kashyap MC; Mandal SK; Sathe V; Sangamwar AT
Mol Pharm; 2021 Jun; 18(6):2334-2348. PubMed ID: 34003656
[TBL] [Abstract][Full Text] [Related]
23. Polymer/Amorphous Salt Solid Dispersions of Ciprofloxacin.
Mesallati H; Tajber L
Pharm Res; 2017 Nov; 34(11):2425-2439. PubMed ID: 28875408
[TBL] [Abstract][Full Text] [Related]
24. API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility.
Ford L; Tay E; Nguyen TH; Williams HD; Benameur H; Scammells PJ; Porter CJH
RSC Adv; 2020 Mar; 10(22):12788-12799. PubMed ID: 35492138
[TBL] [Abstract][Full Text] [Related]
25. Effect of counterion on the phase behaviour during lyophilization of indomethacin salt forms.
Kumar L; Baheti A; Mokashi A; Bansal AK
Eur J Pharm Sci; 2011 Sep; 44(1-2):136-41. PubMed ID: 21767640
[TBL] [Abstract][Full Text] [Related]
26. The use of inorganic salts to improve the dissolution characteristics of tablets containing Soluplus®-based solid dispersions.
Hughey JR; Keen JM; Miller DA; Kolter K; Langley N; McGinity JW
Eur J Pharm Sci; 2013 Mar; 48(4-5):758-66. PubMed ID: 23348153
[TBL] [Abstract][Full Text] [Related]
27. The influence of aqueous content in small scale salt screening--improving hit rate for weakly basic, low solubility drugs.
Tarsa PB; Towler CS; Woollam G; Berghausen J
Eur J Pharm Sci; 2010 Sep; 41(1):23-30. PubMed ID: 20553863
[TBL] [Abstract][Full Text] [Related]
28. Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations.
Gupta D; Bhatia D; Dave V; Sutariya V; Varghese Gupta S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30011904
[TBL] [Abstract][Full Text] [Related]
29. Implementing quality by design in pharmaceutical salt selection: a modeling approach to understanding disproportionation.
Merritt JM; Viswanath SK; Stephenson GA
Pharm Res; 2013 Jan; 30(1):203-17. PubMed ID: 22918819
[TBL] [Abstract][Full Text] [Related]
30. Crystal forms of the hydrogen oxalate salt of o-desmethylvenlafaxine.
Dichiarante E; Curzi M; Giaffreda SL; Grepioni F; Maini L; Braga D
J Pharm Pharmacol; 2015 Jun; 67(6):823-9. PubMed ID: 25644936
[TBL] [Abstract][Full Text] [Related]
31. Rationalizing Counterion Selection for the Development of Lipophilic Salts: A Case Study with Venetoclax.
Ryan CD; Griffin BT; O'Shea JP
Mol Pharm; 2024 Jun; 21(6):2981-2992. PubMed ID: 38703358
[TBL] [Abstract][Full Text] [Related]
32. Effect of counterion on the solid state photodegradation behavior of prazosin salts.
Kumar L; Jog R; Singh S; Bansal A
AAPS PharmSciTech; 2013 Jun; 14(2):757-63. PubMed ID: 23595416
[TBL] [Abstract][Full Text] [Related]
33. In Situ Salification in Polar Solvents: a Paradigm for Enabling Drug Delivery of Weakly Ionic Drugs as Amorphous Solid Dispersion.
Nair R; Lamare I; Tiwari NK; Ravi PR; Pillai R
AAPS PharmSciTech; 2018 Jan; 19(1):326-337. PubMed ID: 28721630
[TBL] [Abstract][Full Text] [Related]
34. Preparation and characterization of new salts of tioconazole. Comparison of their dissolution performance.
Moroni AB; Mayoral EP; Lionello DF; Vega DR; Kaufman TS; Calvo NL
Int J Pharm; 2024 Mar; 652():123855. PubMed ID: 38280497
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a rational vs. high throughput approach for rapid salt screening and selection.
Collman BM; Miller JM; Seadeek C; Stambek JA; Blackburn AC
Drug Dev Ind Pharm; 2013 Jan; 39(1):29-38. PubMed ID: 22380522
[TBL] [Abstract][Full Text] [Related]
36. Salt formation improved the properties of a candidate drug during early formulation development.
Sigfridsson K; Ahlqvist M; Lindsjö M; Paulsson S
Eur J Pharm Sci; 2018 Jul; 120():162-171. PubMed ID: 29730322
[TBL] [Abstract][Full Text] [Related]
37. Effect of a counterion on the glass transition temperature (T(g)') during lyophilization of ganciclovir salt forms.
Kumar L; Baheti A; Bansal AK
Mol Pharm; 2011 Feb; 8(1):309-14. PubMed ID: 21133416
[TBL] [Abstract][Full Text] [Related]
38. Fluorimetric determination of procaine in pharmaceutical preparations based on its reaction with fluorescamine.
Segura Carretero A; Cruces-Blanco C; Fernández Peinado S; El Bergmi R; Fernández Gutiérrez A
J Pharm Biomed Anal; 1999 Dec; 21(5):969-74. PubMed ID: 10703964
[TBL] [Abstract][Full Text] [Related]
39. Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.
Williams HD; Ford L; Lim S; Han S; Baumann J; Sullivan H; Vodak D; Igonin A; Benameur H; Pouton CW; Scammells PJ; Porter CJH
J Pharm Sci; 2018 Jan; 107(1):203-216. PubMed ID: 28549907
[TBL] [Abstract][Full Text] [Related]
40. Understanding the tendency of amorphous solid dispersions to undergo amorphous-amorphous phase separation in the presence of absorbed moisture.
Rumondor AC; Wikström H; Van Eerdenbrugh B; Taylor LS
AAPS PharmSciTech; 2011 Dec; 12(4):1209-19. PubMed ID: 21927960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
